NeuRx DPS
Respiratory insufficiency in Spinal Cord Injury & ALS
ApprovedActive
Key Facts
Indication
Respiratory insufficiency in Spinal Cord Injury & ALS
Phase
Approved
Status
Active
Company
About Synapse Biomedical
Synapse Biomedical, founded in 2002, commercializes diaphragm pacing systems to treat chronic respiratory insufficiency. Its core technology, the NeuRx DPS, is an FDA-approved implantable neurostimulator that activates the diaphragm muscle, aiming to wean patients off mechanical ventilation. The company serves spinal cord injury and ALS patients, has treated over 2,000 patients, and operates globally. It is a private, commercial-stage company with a focused pipeline in neurostimulation.
View full company profile